Steroid-refractory severe ulcerative colitis: What are the available treatment options?

Drugs

Volumn 68, Issue 9, 2008, Pages 1157-1167

  Moss, Alan C ^a   Peppercorn, Mark A ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Azathioprine, therapeutic use; Basiliximab, therapeutic use; Ciclosporin, therapeutic use; Corticosteroids, therapeutic use; Infliximab, therapeutic use; Mercaptopurine, therapeutic use; Research and development; Ulcerative colitis, treatment

Indexed keywords

ANTIINFLAMMATORY AGENT; AZATHIOPRINE; BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; METHYLPREDNISOLONE; PREDNISOLONE; TACROLIMUS; VISILIZUMAB;

BACTERIAL INFECTION; CLINICAL TRIAL; COLON RESECTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GINGIVA HYPERPLASIA; HEADACHE; HIRSUTISM; HUMAN; HYPERTENSION; LIVER FUNCTION TEST; MYCOSIS; NEPHROTOXICITY; NEUROTOXICITY; PARESTHESIA; PNEUMONIA; PRACTICE GUIDELINE; REVIEW; SEIZURE; SIDE EFFECT; TREATMENT INDICATION; TREMOR; ULCERATIVE COLITIS; VIRUS INFECTION;

ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL; COLECTOMY; COLITIS, ULCERATIVE; CYCLOSPORINE; DRUG RESISTANCE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKAPHERESIS; RECOMBINANT FUSION PROTEINS; TACROLIMUS;

EID: 44949126471     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200868090-00001     Document Type: Review

References (89)

1. Farmer RG, Easley KA, Rankin GB. Clinical patterns, natural history, and progression of ulcerative colitis: a long-term follow-up of 1116 patients. Dig Dis Sci 1993; 386: 1137-46
2. Sonnenberg A. Time trends of mortality from Crohn's disease and ulcerative colitis. Int J Epidemiol 2007; 364: 890-9
3. Flatmark A, Fretheim B, Gjone E. Early colectomy in severe ulcerative colitis. Scand J Gastroenterol 1975; 104: 427-31
4. Truelove SC, Witts LJ. Cortisone in ulcerative colitis: final report on a therapeutic trial. Br Med J 1955; 24947: 1041-8
5. Bernal I, Manosa M, Domenech E, et al. Predictors of clinical response to systemic steroids in active ulcerative colitis. Dig Dis Sci 2006; 518: 1434-8
6. Jarnerot G, Rolny P, Sandberg-Gertzen H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985; 895: 1005-13
7. Turner D, Walsh CM, Steinhart AH, et al. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 2007; 51: 103-10
8. Cooney RM, Warren BF, Altman DG, et al. Outcome measurement in clinical trials for ulcerative colitis: towards standardisation. Trials 2007; 8: 17
9. Caprilli R, Vernia P, Colaneri O, et al. Blood pH: a test for assessment of severity in proctocolitis. Gut 1976; 1710: 763-9
10. Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut 1996; 386: 905-10
11. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study. N Engl J Med 1987; 31726: 1625-9
12. Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004; 53 Suppl. 5: V1-16
13. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004; 997: 1371-85
14. Benazzato L, D'Inca R, Grigoletto F, et al. Prognosis of severe attacks in ulcerative colitis: effect of intensive medical treatment. Dig Liver Dis 2004; 367: 461-6
15. Chakravarty BJ. Predictors and the rate of medical treatment failure in ulcerative colitis. Am J Gastroenterol 1993; 886: 852-5
16. Ho GT, Mowat C, Goddard CJ, et al. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther 2004; 1910: 1079-87
17. Lindgren SC, Flood LM, Kilander AF, et al. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol 1998; 1010: 831-5
18. Meyers S, Lerer PK, Feuer EJ, et al. Predicting the outcome of corticoid therapy for acute ulcerative colitis: results of a prospective, randomized, double-blind clinical trial. J Clin Gastroenterol 1987; 91: 50-4
19. Sands BE, Tremaine WJ, Sandborn WJ, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001; 72: 83-8
20. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 33026: 1841-5
21. Seo M, Okada M, Yao T, et al. Evaluation of the clinical course of acute attacks in patients with ulcerative colitis through the use of an activity index. J Gastroenterol 2002; 371: 29-34
22. Flood L, Lofberg R, Stierna P, et al. Glucocorticoid receptor mRNA in patients with ulcerative colitis: a study of responders and nonresponders to glucocorticosteroid therapy. Inflamm Bowel Dis 2001; 73: 202-9
23. Sambuelli AM, Negreira SM, Gil AH, et al. Multidrug resistance gene (MDR-1) expression in the colonic mucosa of patients with refractory ulcerative colitis. Acta Gastroenterol Latinoam 2006; 361: 23-32
24. Carbonnel F, Gargouri D, Lémann, et al. Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis. Aliment Pharmacol Ther 2000 mar; 14 (3): 273-9
25. Oshitani N, Kitano A, Fukushima R, et al. Predictive factors for the response of ulcerative colitis patients during the acute-phase treatment. Digestion 1990; 46 (2): 107-13
26. Borel JF, Kis ZL. The discovery and development of cyclosporine (Sandimmune). Transplant Proc 1991; 232: 1867-74
27. Kountouras J, Zavos C, Chatzopoulos D. Immunomodulatory benefits of cyclosporine A in inflammatory bowel disease. J Cell Mol Med 2004; 83: 317-28
28. Ina K, Kusugami K, Shimada M, et al. Suppressive effects of cyclosporine A on neutrophils and T cells may be related to therapeutic benefits in patients with steroid-resistant ulcerative colitis. Inflamm Bowel Dis 2002; 81: 1-9
29. D'Haens G, Lemmens L, Geboes K, et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001; 1206: 1323-9
30. Van Assche G, D'Haens G, Noman M, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003; 1254: 1025-31
31. Garcia-Lopez S, Gomollon-Garcia F, Perez-Gisbert J. Cyclosporine in the treatment of severe attack of ulcerative colitis: a systematic review. Gastroenterol Hepatol 2005; 2810: 607-14
32. Durai D, Hawthorne AB. Review article: how and when to use ciclosporin in ulcerative colitis. Aliment Pharmacol Ther 2005; 2210: 907-16
33. Pham CQ, Efros CB, Berardi RR. Cyclosporine for severe ulcerative colitis. Ann Pharmacother 2006; 401: 96-101
34. Shibolet O, Regushevskaya E, Brezis M, et al. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev 2005; (1): CD004277
35. Actis GC, Aimo G, Priolo G, et al. Efficacy and efficiency of oral microemulsion cyclosporin versus intravenous and soft gelatin capsule cyclosporin in the treatment of severe steroid-refractory ulcerative colitis: an open-label retrospective trial. Inflamm Bowel Dis 1998; 44: 276-9
36. Actis GC, Lagget M, Rizzetto M, et al. Long-term efficacy of oral microemulsion cyclosporin for refractory ulcerative colitis. Minerva Med 2004; 951: 65-70
37. Navazo L, Salata H, Morales S, et al. Oral microemulsion cyclosporine in the treatment of steroid-refractory attacks of ulcerative and indeterminate colitis. Scand J Gastroenterol 2001; 366: 610-4
38. Ortiz V, Nos P, Aguilera V, et al. Cyclosporin in an oral microemulsion as the initial treatment of corticoid-refractory ulcerative colitis [in Spanish]. Gastroenterol Hepatol 2000; 233: 120-2
39. Weber A, Fein F, Koch S, et al. Treatment of ulcerative colitis refractory to steroid therapy by oral microemulsion cyclosporine (Neoral). Inflamm Bowel Dis 2006; 1212: 1131-5
40. Cacheux W, Seksik P, Lemann M, et al. Predictive factors of response to cyclosporine in steroid-refractory ulcerative colitis. Am J Gastroenterol 2008; 103 (3): 637-42
41. Daniel F, Loriot MA, Seksik P, et al. Multidrug resistance gene-1 polymorphisms and resistance to cyclosporine A in patients with steroid resistant ulcerative colitis. Inflamm Bowel Dis 2007; 131: 19-23
42. Rowe FA, Walker JH, Karp LC, et al. Factors predictive of response to cyclosporin treatment for severe, steroid-resistant ulcerative colitis. Am J Gastroenterol 2000; 958: 2000-8
43. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol 1999; 946: 1587-92
44. de Saussure P, Soravia C, Morel P, et al. Low-dose oral micro-emulsion ciclosporin for severe, refractory ulcerative colitis. Aliment Pharmacol Ther 2005; 223: 203-8
45. Haslam N, Hearing SD, Probert CS. Audit of cyclosporin use in inflammatory bowel disease: limited benefits, numerous side-effects. Eur J Gastroenterol Hepatol 2000; 126: 657-60
46. Stack WA, Long RG, Hawkey CJ. Short- and long-term outcome of patients treated with cyclosporin for severe acute ulcerative colitis. Aliment Pharmacol Ther 1998; 1210: 973-8
47. Arts J, D'Haens G, Zeegers M, et al. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis 2004; 102: 73-8
48. de Groen PC, Aksamit AJ, Rakela J, et al. Central nervous system toxicity after liver transplantation: the role of cyclosporine and cholesterol. N Engl J Med 1987; 31714: 861-6
49. Vogt DP, Lederman RJ, Carey WD, et al. Neurologic complications of liver transplantation. Transplantation 1988; 456: 1057-61
50. Campbell S, Ghosh S. Combination immunomodulatory therapy with cyclosporine and azathioprine in corticosteroid-resistant severe ulcerative colitis: the Edinburgh experience of outcome. Dig Liver Dis 2003; 358: 546-51
51. Campbell S, Travis S, Jewell D. Ciclosporin use in acute ulcerative colitis: a long-term experience. Eur J Gastroenterol Hepatol 2005; 171: 79-84
52. Domenech E, Garcia-Planella E, Bernal I, et al. Azathioprine without oral ciclosporin in the long-term maintenance of remission induced by intravenous ciclosporin in severe, steroid-refractory ulcerative colitis. Aliment Pharmacol Ther 2002; 1612: 2061-5
53. Moskovitz DN, Van Assche G, Maenhout B, et al. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol 2006; 46: 760-5
54. Cohen RD, Brodsky AL, Hanauer SB. A comparison of the quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous cyclosporin. Inflamm Bowel Dis 1999; 51: 1-10
55. Braat H, Peppelenbosch MP, Hommes DW. Immunology of Crohn's disease. Ann N Y Acad Sci 2006; 107: 2135-54
56. Aspalter RM, Eibl MM, Wolf HM. Regulation of TCR-mediated T cell activation by TNF-RII. J Leukoc Biol 2003; 744: 572-82
57. Seitz C, Muller P, Krieg RC, et al. A novel p75TNF receptor isoform mediating NFkappa B activation. J Biol Chem 2001; 27622: 19390-5
58. Ina K, Itoh J, Fukushima K, et al. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/ Bax mucosal imbalance. J Immunol 1999; 1632: 1081-90
59. Hassan C, Ierardi E, Burattini O, et al. Tumour necrosis factor alpha down-regulation parallels inflammatory regression in ulcerative colitis patients treated with infliximab. Dig Liver Dis 2007; 399: 811-7
60. Probert CS, Hearing SD, Schreiber S, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003; 527: 998-1002
61. Järnerot G, Hertevig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomised, placebo-controlled study. Gastroenterology 2005 Jun; 128 (7): 1805-11
62. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 35323: 2462-76
63. Gisbert JP, Gonzalez-Lama Y, Mate J. Systematic review: infliximab therapy in ulcerative colitis. Aliment Pharmacol Ther 2007; 251: 19-37
64. Bermejo F, Lopez-Sanroman A, Hinojosa J, et al. Infliximab induces clinical, endoscopic and histological responses in refractory ulcerative colitis. Rev Esp Enferm Dig 2004; 962: 94-101
65. Mamula P, Markowitz JE, Brown KA, et al. Infliximab as a novel therapy for pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr 2002; 343: 307-11
66. Mamula P, Markowitz JE, Cohen LJ, et al. Infliximab in pediatric ulcerative colitis: two-year follow-up. J Pediatr Gastroenterol Nutr 2004; 383: 298-301
67. Serrano MS, Schmidt-Sommerfeld E, Kilbaugh TJ, et al. Use of infliximab in pediatric patients with inflammatory bowel disease. Ann Pharmacother 2001; 357-8: 823-8
68. Jakobovits SL, Jewell DP, Travis SP. Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006. Aliment Pharmacol Ther 2007; 259: 1055-60
69. Kohn A, Daperno M, Armuzzi A, et al. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up. Aliment Pharmacol Ther 2007; 265: 747-56
70. Schluender SJ, Ippoliti A, Dubinsky M, et al. Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis? Dis Colon Rectum 2007; 5011: 1747-53
71. Maser E, Deconda D, Lichtiger S, et al. Cyclosporine (CsA) and infliximab (Inf) as acute salvage therapies for each other, in severe steroid refractory ulcerative colitis (UC) [abstract]. Gastroenterology 2007; 1324: A-180
72. Creed TJ, Norman MR, Probert CS, et al. Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment Pharmacol Ther 2003; 181: 65-75
73. Creed TJ, Probert CS, Norman MN, et al. Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease. Aliment Pharmacol Ther 2006; 2310: 1435-42
74. Plevy S, Salzberg B, Van Assche G, et al. A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. Gastroenterology 2007; 1335: 1414-22
75. Aoki H, Nakamura K, Yoshimatsu Y, et al. Adacolumn selective leukocyte adsorption apheresis in patients with active ulcerative colitis: clinical efficacy, effects on plasma IL-8, and expression of Toll-like receptor 2 on granulocytes. Dig Dis Sci 2007; 526: 1427-33
76. Barta Z, Toth L, Zeher M. Pulse cyclophosphamide therapy for inflammatory bowel disease. World J Gastroenterol 2006; 128: 1278-80
77. Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005; 35224: 2499-507
78. Fellermann K, Tanko Z, Herrlinger KR, et al. Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm Bowel Dis 2002; 85: 317-24
79. Lazzerini M, Martelossi S, Marchetti F, et al. Efficacy and safety of thalidomide in children and young adults with intractable inflammatory bowel disease: long-term results. Aliment Pharmacol Ther 2007; 254: 419-27
80. Musch E, Andus T, Malek M, et al. Successful treatment of steroid refractory active ulcerative colitis with natural interferon-beta: an open long-term trial. Z Gastroenterol 2007; 4512: 1235-40
81. Stremmel W, Ehehalt R, Autschbach F, et al. Phosphatidylcholine for steroid-refractory chronic ulcerative colitis: a randomized trial. Ann Intern Med 2007; 1479: 603-10
82. Metcalf AM. Elective and emergent operative management of ulcerative colitis. Surg Clin North Am 2007; 873: 633-41
83. Lichtenstein GR, Cohen R, Yamashita B, et al. Quality of life after proctocolectomy with ileoanal anastomosis for patients with ulcerative colitis. J Clin Gastroenterol 2006; 408: 669-77
84. Hahnloser D, Pemberton JH, Wolff BG, et al. Results at up to 20 years after ileal pouch-anal anastomosis for chronic ulcerative colitis. Br J Surg 2007; 943: 333-40
85. Meagher AP, Farouk R, Dozois RR, et al. J ileal pouch-anal anastomosis for chronic ulcerative colitis: complications and long-term outcome in 1310 patients. Br J Surg 1998; 856: 800-3
86. Mahadevan U, Sandborn WJ. Diagnosis and management of pouchitis. Gastroenterology 2003; 1246: 1636-50
87. Waljee A, Waljee J, Morris AM, et al. Threefold increased risk of infertility: a meta-analysis of infertility after ileal pouch anal anastomosis in ulcerative colitis. Gut 2006; 5511: 1575-80
88. Wikland M, Jansson I, Asztely M, et al. Gynaecological problems related to anatomical changes after conventional proctocolectomy and ileostomy. Int J Colorectal Dis 1990; 51: 49-52
89. Hyde GM, Jewell DP, Kettlewell MG, et al. Cyclosporin for severe ulcerative colitis does not increase the rate of perioperative complications. Dis Colon Rectum 2001; 4410: 1436-40